nach oben

Erschienen in:

01.02.2016 | Original Article

CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation

verfasst von: Ankit Anand, Prathima Anandi, Natasha A. Jain, Kit Lu, Neil Dunavin, Christopher S. Hourigan, Robert Q. Le, Puja D. Chokshi, Sawa Ito, David F. Stroncek, Marianna Sabatino, A. John Barrett, Minoo Battiwalla

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

The purpose of the present study was to evaluate the impact of ex vivo T cell depleted (TCD) by CD34+ selection on the incidence and severity of oropharyngeal mucositis (OM) after myeloablative allogeneic stem cell transplant (allo-SCT) with total body irradiation (TBI) conditioning. This approach has the advantage of avoiding methotrexate for graft versus host disease (GVHD) prophylaxis.

Patients and Methods

We analyzed the incidence and severity of OM in a cohort of 105 consecutive patients who underwent CD34+ selected (peripheral blood stem cells (PBSCs) from human leukocyte antigen (HLA)-identical siblings) allo-SCT with total body irradiation (TBI) conditioning. OM was graded by the World Health organization (WHO) and the Bearman regimen-related toxicity (RRT) scales.

Results

The incidence of WHO grade 3–4 OM was 34.3 %. There were no cases of grade 3–4 OM by the RRT scale. Significant correlation was found between the severity of OM and the use of intravenous (IV) narcotic medications (r ² = 0.15, p = 0.004), total parenteral nutrition (TPN; r ² = 0.68, p < 0.001), and hospital length of stay (LOS) (r ² = 0.12, p = 0.01).

Discussion

TBI-induced OM can inflict significant morbidity in the early transplant period, and the incidence of WHO grade 3–4 OM can exceed 50 % when methotrexate is used for GVHD prophylaxis. In the CD34+ selected setting, methotrexate is avoided and the incidence of WHO grade 3–4 OM, use of TPN, and need for narcotic analgesia appear to be lower than historic evidence from standard T-replete allogeneic transplantation.

Conclusion

We conclude that toxicity from OM is tolerable in CD34+ selected allo-SCT and should be prospectively measured in randomized trials comparing CD34+ selection versus T-replete transplantation.

Nur mit Berechtigung zugänglich

Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351(25):2590–2598. doi:10.1056/NEJMoa040125 PubMedCrossRef

Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T, Fuchs HJ, Haskins MN, Horowitz MM, Martin PJ, McGuire DB, Mullane K, Oster G (2002) Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Investig 20(5-6):793–800CrossRef

Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ (2014) Oral mucositis in cancer treatment: Natural history, prevention and treatment. Mol Clin Oncol 2(3):337–340. doi:10.3892/mco.2014.253 PubMedPubMedCentral

Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, Harrison MJ, Ho V, Alyea E, Lee SJ, Soiffer R, Sonis S, Antin JH (2005) Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 11(5):383–388. doi:10.1016/j.bbmt.2005.02.006 CrossRef

Busemann C, Wilfert H, Neumann T, Kiefer T, Dolken G, Kruger WH (2011) Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation. Onkologie 34(10):518–524. doi:10.1159/000332131 PubMedCrossRef

Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R, Fraser CJ, Scarffe JH (2000) Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 110(2):292–299PubMedCrossRef

Facchini L, Martino R, Ferrari A, Pinana JL, Valcarcel D, Barba P, Granell M, Delgado J, Briones J, Sureda A, Brunet S, Sierra J (2012) Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning. Eur J Haematol 88(1):46–51. doi:10.1111/j.1600-0609.2011.01724.x PubMedCrossRef

Nooka AK, Johnson HR, Kaufman JL, Flowers CR, Langston A, Steuer C, Graiser M, Ali Z, Shah NN, Rangaraju S, Nickleach D, Gao J, Lonial S, Waller EK (2014) Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. doi:10.1016/j.bbmt.2014.02.025

Langner S, Staber P, Schub N, Gramatzki M, Grothe W, Behre G, Rabitsch W, Urban C, Linkesch W, Neumeister P (2008) Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 42(4):275–279. doi:10.1038/bmt.2008.157 PubMedCrossRef

10.

Schmidt E, Thoennissen NH, Rudat A, Bieker R, Schliemann C, Mesters RM, Zuhlsdorf M, Muller-Tidow C, Berdel WE (2008) Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol Off J Eur Soc Med Oncol ESMO 19(9):1644–1649. doi:10.1093/annonc/mdn179 CrossRef

11.

Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, Ariail KS, Keener CL, Li S, Liu H, Farin FM, Potter JD (2001) Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98(1):231–234PubMedCrossRef

12.

Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, Kalaycio M (2004) A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 34(7):621–625. doi:10.1038/sj.bmt.1704647 PubMedCrossRef

13.

Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW, Waller EK, Grupp S, McCarthy P, Wu J, Hu ZH, Carter SL, Horowitz MM, Antin JH (2014) Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 124(8):1372–1377. doi:10.1182/blood-2014-04-567164 PubMedPubMedCentralCrossRef

14.

Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP 3rd, Keever-Taylor CA, O'Reilly RJ (2011) Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 17(9):1343–1351. doi:10.1016/j.bbmt.2011.02.002 CrossRef

15.

Ho VT (2011) Ex vivo T cell depletion of allogeneic PBSC as acute and chronic GVHD prophylaxis after myeloablative HCT: time to reconsider? Biol Blood Marrow Transplant 17(8):1112–1113. doi:10.1016/j.bbmt.2011.02.005 PubMedCrossRef

16.

Jakubowski AA, Small TN, Kernan NA, Castro-Malaspina H, Collins N, Koehne G, Hsu KC, Perales MA, Papanicolaou G, van den Brink MR, O'Reilly RJ, Young JW, Papadopoulos EB (2011) T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant 17(9):1335–1342. doi:10.1016/j.bbmt.2011.01.005 PubMedPubMedCentralCrossRef

17.

Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, O'Reilly RJ, Soiffer RJ (2012) Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 30(26):3194–3201. doi:10.1200/JCO.2012.41.7071 PubMedPubMedCentralCrossRef

18.

Goldberg JD, Zheng J, Castro-Malaspina H, Jakubowski AA, Heller G, van den Brink MR, Perales MA (2013) Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 48(1):99–104. doi:10.1038/bmt.2012.115 PubMedPubMedCentralCrossRef

19.

Sonis ST, Eilers JP, Epstein JB, LeVeque FG, Liggett WH Jr, Mulagha MT, Peterson DE, Rose AH, Schubert MM, Spijkervet FK, Wittes JP (1999) Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 85(10):2103–2113PubMedCrossRef

20.

Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED (1988) Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol Off J Am Soc Clin Oncol 6(10):1562–1568

21.

Blijlevens N, Sonis S (2007) Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol Off J Eur Soc Med Oncol ESMO 18(5):817–826. doi:10.1093/annonc/mdl332 CrossRef

22.

Jagasia MH, Abonour R, Long GD, Bolwell BJ, Laport GG, Shore TB, Durrant S, Szer J, Chen MG, Lizambri R, Waller EK (2012) Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant 47(10):1350–1355. doi:10.1038/bmt.2011.261 PubMedCrossRef

23.

Elting LS, Shih YC, Stiff PJ, Bensinger W, Cantor SB, Cooksley C, Spielberger R, Emmanoulides C (2007) Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 13(7):806–813. doi:10.1016/j.bbmt.2007.03.004 CrossRef

24.

Blazar BR, Weisdorf DJ, Defor T, Goldman A, Braun T, Silver S, Ferrara JL (2006) Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 108(9):3216–3222. doi:10.1182/blood-2006-04-017780 PubMedPubMedCentralCrossRef

25.

Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM (2004) Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol Off J Am Soc Clin Oncol 22(7):1268–1275. doi:10.1200/jco.2004.05.147 CrossRef

26.

Suthandiram S, Gan GG, Zain SM, Bee PC, Lian LH, Chang KM, Ong TC, Mohamed Z (2014) Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics 15(11):1479–1494. doi:10.2217/pgs.14.97 PubMedCrossRef

27.

den Hoed MA, Lopez-Lopez E, Te Winkel ML, Tissing W, de Rooij JD, Gutierrez-Camino A, Garcia-Orad A, den Boer E, Pieters R, Pluijm SM, de Jonge R, van den Heuvel-Eibrink MM (2014) Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. doi:10.1038/tpj.2014.63

28.

Robien K, Schubert MM, Chay T, Bigler J, Storb R, Yasui Y, Potter JD, Ulrich CM (2006) Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation. Bone Marrow Transplant 37(8):799–800. doi:10.1038/sj.bmt.1705330 PubMedCrossRef

29.

Rocha V, Porcher R, Fernandes JF, Filion A, Bittencourt H, Silva W Jr, Vilela G, Zanette DL, Ferry C, Larghero J, Devergie A, Ribaud P, Skvortsova Y, Tamouza R, Gluckman E, Socie G, Zago MA (2009) Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 23(3):545–556. doi:10.1038/leu.2008.323 PubMedCrossRef

30.

Murphy NM, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R, King-Kallimanis B, Holdsworth R, McCluskey J, Tait BD (2012) The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 18(5):722–730. doi:10.1016/j.bbmt.2011.09.001 CrossRef

Titel: CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation
verfasst von: Ankit Anand
Prathima Anandi
Natasha A. Jain
Kit Lu
Neil Dunavin
Christopher S. Hourigan
Robert Q. Le
Puja D. Chokshi
Sawa Ito
David F. Stroncek
Marianna Sabatino
A. John Barrett
Minoo Battiwalla
Publikationsdatum: 01.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 2/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-2848-9

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation